Medline.ru - | Иммуногенетические факторы патогенеза HCV−инфекции

Reference list

1. Abrams J.R., Kelley S.L., Hayes E. et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells // J. Exp. Med. – 2000. – Vol. 192, №5. – R. 681 – 694.

2. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome // Semin Liver Dis. – 2000. – Vol. 20, №1. – P. 17 – 35.

3. Alves Pedroso M.L., Boldt A.B., Pereira-Ferrari L, et al. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy // Clin. Exp. Immunol. – 2008. – Vol. 152, №2. – R. 258 – 264.

4. Bisbal C., Silverman R.H. Diverse functions of RNase L and implications in

pathology // Biochimie. – 2007. – Vol. 89, № 6-7. – R. 789 – 798.

5. Bour-Jordan H., Bluestone J.A. Regulating the regulators: costimulatory signals

control the homeostasis and function of regulatory T cells // Immunol. Rev. – 2009. Vol. 229,

№1. – R. 41 – 66.

6. Brown E.E., Zhang M., Zarin-Pass R., et al. MBL2 and hepatitis C virus infection

among injection drug users // BMC Infect. Dis. – 2008. – Vol. 1, №8. – R. 57.

7. Brown K.S., Ryder S.D., Irving W.L., et al. Mannan binding lectin and viral

hepatitis // Immunol. Lett. – 2007. – Vol. 108, №1. – P. 34 – 44.

8. Carreno B.M., Bennett F., Chau T.A. et al. CTLA-4 (CD152) can inhibit T cell

activation by two different mechanisms depending on its level of cell surfaceexpression // J.

Immunol. – 2000. – Vol. 165, №3. – P. 1352 – 1356.

9. Casey G., Neville P.J., Plummer S.J. et al. RNASEL Arg462Gln variant is

implicated in up to 13% of prostate cancer cases // Nat. Genet. – 2002. – Vol. 32, №4. – R. 581 – 583.

10. Cedzynski M., Szemraj J., Swierzko A.S. et al. Mannan-binding lectin insufficiency

in children with recurrent infections of the respiratory system // Clin. Exp. Immunol. – 2004. –

Vol. 136, №2. – R. 304 – 311.

11. Chambers C.A., Sullivan T.J., Allison J.P. Lymphoproliferation in CTLA-4-

deficient mice is mediated by costimulation-dependent activation of CD4+ T cells // Immunity. –

1997. – Vol. 7, №6. – R. 885 – 895.

12. Chaplin D.D. Overview of the immune response // J. Allergy Clin. Immunol. – 2010. – Vol. 125, №2, Suppl. 2. – R. 3 – 23.

13. Cho M.L., Kim J.Y., Ko H.J. et al. The MCP-1 promoter -2518 polymorphism in

Behcet's disease: correlation between allele types, MCP-1 production and clinical symptoms

among Korean patients // Autoimmunity. – 2004. – Vol. 37, №1. – R. 77 – 80.

14. Collins M., Ling V., Carreno B.M. The B7 family of immune-regulatory ligands //

Genome. Biol. – 2005 – Vol. 6, №6. – R. 223.

15. Crawford A., Wherry E.J. The diversity of costimulatory and inhibitory receptor

pathways and the regulation of antiviral T cell responses // Curr. Opin. Immunol. – 2009. –

Vol. 21, №2. – R. 179 – 186.

16. Dariavach P., Mattei M.G., Golstein P., Lefranc MP. Human Ig superfamily CTLA-

4 gene: chromosomal localization and identity of protein sequence between murine and human

CTLA-4 cytoplasmic domains // Eur. J. Immunol. – 1988. – Vol. 18, №12. – R. 1901 – 1905.

17. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant

protein-1 (MCP-1): an overview // J. Interferon Cytokine Res. – 2009. – Vol. 29, №6. – R. 313 – 326.

18. Dobaczewski M., Frangogiannis N.G. Chemokines and cardiac fibrosis // Front.

Biosci. – 2009. – Vol. 1, №1. – R. 391 – 405.

19. Donner H., Seidl C., Braun J. et al. CTLA4 gene haplotypes cannot protect from

IDDM in the presence of high-risk HLA DQ8 or DQ2 alleles in German families // Diabetes. –

1998. – Vol. 47, №7. – R. 1158 – 1160.

20. Dore G.J., Freeman A.J., Law M., Kaldor J.M. Is severe liver disease a common

outcome for people with chronic hepatitis C? // J. Gastroenterol. Hepatol. – 2002. – Vol. 17, №4. – R. 423 – 430.

21. Dumestre-Perard C., Ponard D., Arlaud G.J. et al. Evaluation and clinical interest of

mannan binding lectin function in human plasma // Mol. Immunol. – 2002. – Vol. 39, № 7-8. – R. 465 – 473.

22. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive

immune responses // Cel.l Res. – 2010. - – Vol. 20, № 1. – R. 34 – 50.

23. Dunning A.M., Ellis P.D., McBride S. A transforming growth factorbeta1 signal

peptide variant increases secretion in vitro and is associated with increased incidence of invasive

breast cancer // Cancer Res. – 2003. – Vol. 63, № 10 – R. 2610 – 2615

24. Finzer P., Soto U., Delius H. et al. Differential transcriptional regulation of the

monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells: the role of the chromatin structure and AP-1 composition // Oncogene – 2000. – Vol. 19, № 29. – R. 3235 – 3244.

25. Friedman S.L. Liver fibrosis - from bench to bedside // J. Hepatol. – 2003. – Vol. 38, Suppl 1. – P. 38 – 53.

26. Garred P., Madsen H.O. Genetic Susceptibility to Sepsis: A Possible Role for

Mannose-binding Lectin // Curr. Infect Dis. Rep. – 2004 – Vol. 6, № 5. – R. 367 – 373.

27. Garred P., Pressler T., Lanng S. et al. Mannose-binding lectin (MBL) therapy in an

MBL-deficient patient with severe cystic fibrosis lung disease // Pediatr. Pulmonol. – 2002. –

Vol. 33, № 3. – R. 201 -207.

28. Gewaltig J., Mangasser-Stephan K., Gartung C. et al. Association of

polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of

HCV-induced liver fibrosis // Clin. Chim. Acta. – 2002. – Vol. 316, № 1-2. – R. 83 – 94.

29. Glas J., Torok H.P., Tonenchi L. et al. The -2518 promotor polymorphism in the

MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection //

Gastroenterology. – 2004. – Vol. 126, № 7. – R. 1930 – 1931.

30. Gleizes P.E., Munger J.S., Nunes I. et al. TGF-beta latency: biological significance

and mechanisms of activation // Stem. Cells. – 1997. – Vol. 15, № 3. – R. 190 – 197.

31. Hardie W.D., Le Cras T.D., Jiang K. et al. Conditional expression of transforming

growth factor-alpha in adult mouse lung causes pulmonary fibrosis // Am. J. Physiol. Lung Cell.

Mol. Physiol. – 2004. – Vol. 286, № 4. – R. 741 – 749.

32. Hart M.L., Saifuddin M., Spear G.T. Glycosylation inhibitors and neuraminidase

enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding

lectin // J. Gen. Virol. – 2003. – Vol. 84, № 2. – R. 353 – 360.

33. Kilpatrick D.C., Delahooke T.E., Koch C., Turner M.L., Hayes P.C. Mannanbinding

lectin and hepatitis C infection // Clin. Exp. Immunol. – 2003. – Vol. 132, № 1 – R. 92 – 95.

34. Hodi F.S. Cytotoxic T-lymphocyte-associated antigen-4 // Clin. Cancer Res. –

2007. – Vol. 13, № 18, Suppel. 1. – R. 5238 – 5242.

35. Hokeness K.L., Kuziel W.A., Biron C.A., Salazar-Mather T.P. Monocyte

chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced

inflammatory responses and antiviral defense in liver // J. Immunol. – 2005. – Vol. 174, № 3. – R. 1549 – 1556.

36. Ip W.K., Lau Y.L. Role of mannose-binding lectin in the innate defense against

Candida albicans: enhancement of complement activation, but lack of opsonic function, in

phagocytosis by human dendritic cells // J. Infect. Dis. – 2004. – Vol. 190, № 3. – R. 632 – 640.

37. Karrer S., Bosserhoff A.K., Weiderer P. et al. The -2518 promotor polymorphism in

the MCP-1 gene is associated with systemic sclerosis // J. Invest. Dermatol. – 2005. – Vol. 124,

№ 1. – R. 92 – 98.

38. Kelly P., Jack D.L., Naeem A. et al. Mannose-binding lectin is a component of

innate mucosal defense against Cryptosporidium parvum in AIDS // Gastroenterology. – 2000. –

Vol. 119, № 5. – R. 1236 – 1242.

39. Kinnman N., Andersson U., Hultcrantz R. In situ expression of transforming growth

factor-beta1-3, latent transforming growth factor-beta binding protein and tumor necrosis factoralpha

in liver tissue from patients with chronic hepatitis C // Scand. J. Gastroenterol. – 2000. –

Vol. 35, № 12. – R. 1294 – 1300.

40. Kouki T., Gardine C.A., Yanagawa T., Degroot L.J. Relation of three

polymorphisms of the CTLA-4 gene in patients with Graves’disease // J. Endocrinol. Invest. –

2002. – Vol. 25, № 3. – R. 208 – 213.

41. Koutsounaki E., Goulielmos G.N., Koulentaki M., et al. Mannose-binding lectin

MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients // J. Clin.

Immunol. – 2008. – Vol. 28, № 5. – R. 495 – 500.

42. Larsen F., Madsen H.O., Sim R.B. et al. Disease-associated mutations in human

mannose-binding lectin compromise oligomerization and activity of the final protein // J. Biol.

Chem. – 2004. – Vol. 14, № 20. – R. 21302 – 21311.

43. Le Roy F., Silhol M., Salehzada T., Bisbal C. Regulation of mitochondrial mRNA

stability by RNase L is translation-dependent and controls IFNalpha-induced apoptosis // Cell.

Death Differ. – 2007. – Vol. 14, № 8. – R. 1406 – 1413.

44. Letendre S., Marquie-Beck J., Singh K.K. et al. The monocyte chemotactic

protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal

fluid // J. Neuroimmunol. – 2004. – Vol. 157, № (1-2). – R. 193 – 196.

45. Ligers A., Teleshova N., Masterman T. et al. CTLA-4 gene expression is influenced

by promoter and exon 1 polymorphisms // Genes Immun. – 2001. – Vol. 2, № 3. – R. 145 – 152.

46. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation // N.

Engl. J. Med. – 1998. – Vol. 338, № 7. – R. 436 – 445.

47. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases

from behind the scenes into the spotlight // Am. J. Pathol. – 2007. – Vol. 171, № 3. – R. 715 – 727.

48. Martin P., Lerner A., Johnson L. et al. Inherited mannose-binding lectin deficiency

as evidenced by genetic and immunologic analyses: association with severe recurrent

infections // Ann. Allergy Asthma Immunol. – 2003. – Vol. 91, № 4. – R. 386 – 392.

49. Matsushita M., Hijikata M., Ohta Y. et al. Hepatitis C virus infection and mutations

of mannose-binding lectin gene MBL // Arch. Virol. – 1998. – Vol. 143, № 4. – R. 645 – 651.

50. Matsushita M., Hijikata M., Matsushita M. et al. Association of mannose-binding

lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in

Japanese patients // J. Hepatol. – 1998. – Vol. 29, № 5. – R. 695 – 700

51. Maurer M., Loserth S., Kolb-Maurer A. et al. A polymorphism in the human

cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation //

Immunogenetics. – 2002. – Vol. 54, № 1. – R. 1 – 8

52. Muhlbauer M., Bosserhoff A.K., Hartmann A. et al. A novel MCP-1 gene

polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver

disease // Gastroenterology. – 2003. – Vol. 125, №4. – R. 1085 – 1093.

53. Nahon P, Sutton A., Rufat P., et al. Chemokine system polymorphisms, survival

and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis //

World J. Gastroenterol. – 2008. – Vol. 14, № 5. – R. 713 – 719.

54. Najafian N., Sayegh M.H. CTLA4-Ig: a novel immunosuppressive agent // Expert.

Opin. Investig. Drugs. – 2000. – Vol. 9, № 9. – R. 2147 – 2157.

55. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consensus

and State-of-the-Science Statements. – 2002, – Vol. 19, №3, – R.30.

56. Oaks M.K., Hallett K.M., Penwell R.T. et al. A native soluble form of CTLA-4 //

Cell Immunol. – 2000. – Vol. 201, № 2. – R. 144 – 153.

57. Ostrov D.A., Shi W., Schwartz J.C. et al. Structure of murine CTLA-4 and its role

in modulating T cell responsiveness // Science. – 2000. – Vol. 290, № 5492. – R. 816 – 819.

58. Pangburn M.K., Ferreira V.P., Cortes C. Discrimination between host and

pathogens by the complement system // Vaccine. – 2008. Vol. 26, Suppl 8. – P. 15 – 21.

59. Park Y.J., Chung H.K., Park D.J. et al. Polymorphism in the promoter and exon 1 of

thecytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans // Thyroid. – 2000. – Vol. 10, № 6. – R. 453 – 459.

60. Patel K., Muir A.J., McHutchison J.G. Diagnosis and treatment of chronic hepatitis

C infection // BMJ. – 2006. – Vol. 332, № 7548. – R. 1013 – 1017.

61. Peterslund N.A., Koch C., Jensenius J.C., Thiel S. Association between deficiency

of mannose-binding lectin and severe infections after chemotherapy // Lancet. – 2001. –

Vol. 358, № 9282. – R. 637 – 638.

62. Petri B., Phillipson M., Kubes P. The physiology of leukocyte recruitment: an in

vivo perspective // J. Immunol. – 2008. – Vol. 180, № 10. – R. 6439 – 6446.

63. Powell E.E., Edwards-Smith C.J., Hay J.L., Host genetic factors influence disease

progression in chronic hepatitis C // Hepatology. – 2000. – Vol. 31, № 4. – R. 828 – 833

64. Poynard T., Ratziu V., Benmanov Y., Fibrosis in patients with chronic hepatitis C:

detection and significance // Semin. Liver Dis. – 2000. – Vol. 20, № 1. – R. 47 – 55.

65. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between

induction, signalling, antiviral responses and virus countermeasures // J. Gen. Virol. – 2008. – Vol. 89, № 1. – R. 1 – 47.

66. Ray S., Broor S.L., Vaishnav Y. et al. Transforming growth factor beta in hepatitis

C virus infection: in vivo and in vitro findings // J. Gastroenterol. Hepatol. – 2003. – Vol. 18, № 4. – R. 393 – 403.

67. Rovin B.H., Lu L., Saxena R. A novel polymorphism in the MCP-1 gene regulatory

region that influences MCP-1 expression // Biochem. Bioph. Res. Com. – 1999. – Vol. 259. – R. 344 – 348.

68. Roy S., Knox K., Segal S. et al. MBL genotype and risk of invasive pneumococcal

disease: a case-control study // Lancet. – 2002. – Vol. 359, № 9317. – R. 1569 – 1573.

69. Rudd C.E., Taylor A., Schneider H. CD28 and CTLA-4 coreceptor expression and

signal transduction // Immunol. Rev. – 2009. – Vol. 229, № 1. – R. 12 – 26.

70. Sadler A.J., Williams B.R. Interferon-inducible antiviral effectors // Nat. Rev.

Immunol. – 2008. – Vol. 8, № 7. – R. 559 – 568.

71. Sasaki K., Tsutsumi A., Wakamiya N. et al. Mannose-binding lectin

polymorphisms in patients with hepatitis C virus infection // Scand. J. Gastroenterol. – 2000. –

Vol. 35, № 9. – R. 960 – 965.

72. Segat L., Silva Vasconcelos L.R., et al. Association of polymorphisms in the first

exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection // Clin. Immunol. – 2007. – Vol. 124, № 1. – R. 13 – 17.

73. Seki E., de Minicis S., Inokuchi S., Taura K., Miyai K., van Rooijen N., Schwabe

R.F., Brenner D.A. CCR2 promotes hepatic fibrosis in mice // Hepatology. – 2009. – Vol. 50,

№ 1. – R. 185 – 197.

74. Si Y., Tsou C.L., Croft K., Charo I.F. CCR2 mediates hematopoietic stem and

progenitor cell trafficking to sites of inflammation in mice // J. Clin. Invest. – 2010. – Vol. 120,

№ 4. – R. 1192 – 1203.

75. Silverman R.H. A scientific journey through the 2-5A/RNase L system // Cytokine

Growth. Factor Rev. – 2007. – Vol. 18, № 5-6. – R. 381 – 388.

76. Silverman R.H. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L

during the interferon antiviral response // J. Virol. – 2007. – Vol. 81, № 23. – R. 12720 – 12729.

77. Soo H.M., Garzino-Demo A., Hong W. et al. Expression of a full-length hepatitis C

virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES // Virology. –

2002. – Vol. 303, № 2. – R. 253 – 277.

78. Sumiya M., Super M., Tabona P. et al. Molecular basis of opsonic defect in

immunodeficient children // Lancet. – 1991. – Vol. 337, № 8757. – R. 1569 – 1570.

79. Summerfield J.A., Ryder S., Sumiya M. et al. Mannose binding protein gene

mutations associated with unusual and severe infections in adults // Lancet. – 1995. – Vol. 345,

№ 8954. – R. 886 – 889.

80. Summerfield J.A., Sumiya M., Levin M., Turner M.W. Association of mutations in

mannose binding protein gene with childhood infection in consecutive hospital series // BMJ. –

1997. – Vol. 314, № 7089. – R. 1229 – 1232.

81. Tag C.G., Mengsteab S., Hellerbrand C. et al. Analysis of the transforming growth

factor-beta1 (TGF-beta1) codon 25 gene polymorphism by LightCycler-analysis in patients with

chronic hepatitis C infection // Cytokine. – 2003. – Vol. 24, № 5. – R. 173 – 181.

82. Taylor A.W. Review of the activation of TGF-beta in immunity // J. Leukoc. Biol. –

2009. – Vol. 85, № 1. – R. 29 – 33.

83. Terai I., Kobayashi K., Matsushita M. et al. Relationship between gene

polymorphisms of mannose-binding lectin (MBL) and two molecular forms of MBL // Eur. J.

Immunol. – 2003. – Vol. 33, № 10. – R. 2755 – 2763.

84. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune

attenuator // Immunity. – 1997. – Vol. 7, № 4. – R. 445 – 450.

85. Vaidya B., Oakes E.J., Imrie H. et al. CTLA4 gene and Graves' disease: association

of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the

promoter polymorphism // Clin. Endocrinol. – 2003. – Vol. 58, № 6. – R. 732 – 735.

86. Valdimarsson H., Stefansson M., Vikingsdottir T. et al. Reconstitution of

opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans //

Scand. J. Immunol. – 1998. – Vol. 48, № 2. – R. 116 – 123.

87. Valdimarsson H., Vikingsdottir T., Bang P. et al. Human plasma-derived mannosebinding

lectin: a phase I safety and pharmacokinetic study // Scand. J. Immunol. – 2004. –

Vol. 59, № 1. – R. 97 – 102.

88. Valdimarsson H. Infusion of plasma-derived mannan-binding lectin (MBL) into

MBL-deficient humans // Biochem. Soc. Trans. – 2003. – Vol. 31, № 4. – R. 768 – 769.

89. van de Wetering J.K., van Golde L.M., Batenburg J.J. Collectins: players of the

innate immune system // Eur. J. Biochem. – 2004. – Vol. 271, № 7. – R. 1229 – 1249.

90. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system:

turning lymphocytes off // Science. – 1998. – Vol. 280, № 5361. – R. 243 – 248.

91. Verrecchia F., Mauviel A. Transforming growth factor-beta and fibrosis // World J.

Gastroenterol. – 2007. – Vol. 13, № 22. – R. 3056 – 3062.

92. Vidigal P.G., Germer J.J., Zein N.N. Polymorphisms in the interleukin-10, tumor

necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients

treated with interferon and ribavirin // J. Hepatol. – 2002. – Vol. 36, № 2. – R. 271 – 277.

93. Wang H., Mengsteab S., Tag C.G. et al. Transforming growth factor-beta1 gene

polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic

hepatitis C infection // World J G.astroenterol. – 2005. – Vol. 11, № 13. – R. 1929 – 1936.

94. Wang S., Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family //

Cell. Mol. Immunol. – 2004. – Vol. 1, № 1. – R. 37 – 42.

95. Washenberger C.L., Han J.Q., Kechris K.J., Jha B.K., Silverman R.H., Barton D.J.

Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L // Virus Res. – 2007. – Vol. 130, № 1–2. – R. 85 – 95.

96. Wynn T.A. Cellular and molecular mechanisms of fibrosis // J. Pathol. – 2008.

– Vol. 214, № 2. – R. 199 – 210.

97. Xiang Y., Wang Z., Murakami J. et al. Effects of RNase L mutations associated

with prostate cancer on apoptosis induced by 2',5'-oligoadenylates // Cancer Res. – 2003. – Vol. 63, № 20. – R. 6795 – 67801.

98. Yee L.J., Perez K.A., Tang J. et al. Association of CTLA4 polymorphisms with

sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection // J.

Infect. Dis. – 2003. – Vol. 187, № 8. – R. 1264 – 1271.

99. Yokota M., Ichihara S., Lin T.L. et al. Association of a T29-->C polymorphism of

the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in

Japanese // Circulation. – 2000. – Vol. 101, № 24. – R. 2783 – 2787